Related Experiment Video
Updated: Dec 28, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB
Evelina Miele1,2,3, Luana Abballe4, Gian Paolo Spinelli5,6
1Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, 00161, Rome, Italy. evelina.miele@opbg.net.
Background:
Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient's survival. However, BRAF-mutated CRC patients remain unresponsive to available therapies with RAF inhibitors (RAFi) alone or combined with ErbB inhibitors (ErbBi). These unmet needs require further exploitation of oncogenic signaling in order to set up individualized treatments.
Methods:
To this end, we tested the efficacy of single agent or combined treatments using the BRAFi, vemurafenib and two different ErbBi: panitumumab and afatinib in CRC cells characterized by different molecular phenotypes.
Results:
Combination strategies with BRAFi and ErbBi achieved a better response in BRAFV600E mutated cells expressing high levels of ErbB2.
Conclusions:
Our findings support the importance of ErbB2 evaluation in BRAF-mutated CRC patients and its role as a positive predictor factor of response to BRAFi/ErbBi combination.
Insights
BRAF-mutated colorectal cancer (CRC) patients show limited response to RAF inhibitors (RAFi) alone. Combination therapy with RAF inhibitors and ErbB inhibitors (ErbBi) shows promise, particularly in patients with high ErbB2 expression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Colorectal cancer (CRC) is a complex, heterogeneous disease with numerous genetic alterations.
- Targeted therapies have improved survival, but BRAF-mutated CRC remains challenging.
- BRAF-mutated CRC patients often do not respond to RAF inhibitors (RAFi) or RAF inhibitor/ErbB inhibitor (ErbBi) combinations.
Purpose of the Study:
- To evaluate the efficacy of single-agent and combination therapies involving BRAF inhibitors (BRAFi) and ErbB inhibitors (ErbBi).
- To investigate treatment response in colorectal cancer cells with diverse molecular phenotypes.
- To identify predictive biomarkers for treatment response in BRAF-mutated CRC.
Main Methods:
- Testing BRAFi (vemurafenib) and ErbBi (panitumumab, afatinib) as single agents and in combination.
- Utilizing colorectal cancer cell lines with varying molecular characteristics.
- Assessing treatment efficacy across different cellular phenotypes.
Main Results:
- Combination therapy of BRAFi and ErbBi demonstrated enhanced response in BRAF-mutated CRC cells.
- High expression levels of ErbB2 were associated with improved treatment outcomes.
- ErbB2 expression acts as a potential predictive factor for combination therapy efficacy.
Conclusions:
- ErbB2 evaluation is crucial for BRAF-mutated CRC patients.
- ErbB2 is a positive predictor of response to BRAFi/ErbBi combination therapy.
- Targeting ErbB2 signaling may improve outcomes for specific CRC patient subgroups.
More Related Videos
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...